SK287558B6 - Soli valsartanu, ich použitie, spôsob ich výroby a farmaceutické prípravky obsahujúce tieto soli - Google Patents

Soli valsartanu, ich použitie, spôsob ich výroby a farmaceutické prípravky obsahujúce tieto soli Download PDF

Info

Publication number
SK287558B6
SK287558B6 SK55-2003A SK552003A SK287558B6 SK 287558 B6 SK287558 B6 SK 287558B6 SK 552003 A SK552003 A SK 552003A SK 287558 B6 SK287558 B6 SK 287558B6
Authority
SK
Slovakia
Prior art keywords
salt
valsartan
water
weak
salts
Prior art date
Application number
SK55-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK552003A3 (en
Inventor
Erwin Marti
Hans Rudolf Oswald
Peter B�Hlmayer
Wolfgang Marterer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287558(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK552003A3 publication Critical patent/SK552003A3/sk
Publication of SK287558B6 publication Critical patent/SK287558B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
SK55-2003A 2000-07-19 2001-07-17 Soli valsartanu, ich použitie, spôsob ich výroby a farmaceutické prípravky obsahujúce tieto soli SK287558B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00115556 2000-07-19
PCT/EP2001/008253 WO2002006253A1 (en) 2000-07-19 2001-07-17 Valsartan salts

Publications (2)

Publication Number Publication Date
SK552003A3 SK552003A3 (en) 2003-07-01
SK287558B6 true SK287558B6 (sk) 2011-02-04

Family

ID=8169294

Family Applications (1)

Application Number Title Priority Date Filing Date
SK55-2003A SK287558B6 (sk) 2000-07-19 2001-07-17 Soli valsartanu, ich použitie, spôsob ich výroby a farmaceutické prípravky obsahujúce tieto soli

Country Status (31)

Country Link
US (5) US20030207930A1 (zh)
EP (1) EP1313714B1 (zh)
JP (1) JP4102664B2 (zh)
KR (1) KR100529658B1 (zh)
CN (2) CN100413852C (zh)
AR (2) AR032758A1 (zh)
AT (1) ATE406355T1 (zh)
AU (2) AU2001289672B2 (zh)
BR (1) BR0112665A (zh)
CA (1) CA2415962C (zh)
CY (1) CY1108559T1 (zh)
CZ (1) CZ303389B6 (zh)
DE (1) DE60135560D1 (zh)
DK (1) DK1313714T3 (zh)
EC (1) ECSP034436A (zh)
ES (1) ES2309090T3 (zh)
HK (1) HK1055963A1 (zh)
HU (1) HU229280B1 (zh)
IL (2) IL153882A0 (zh)
MX (1) MXPA03000525A (zh)
MY (2) MY136446A (zh)
NO (1) NO326504B1 (zh)
NZ (1) NZ523557A (zh)
PE (1) PE20020613A1 (zh)
PL (1) PL205715B1 (zh)
PT (1) PT1313714E (zh)
RU (1) RU2275363C2 (zh)
SI (1) SI1313714T1 (zh)
SK (1) SK287558B6 (zh)
WO (1) WO2002006253A1 (zh)
ZA (1) ZA200300285B (zh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2275363C2 (ru) 2000-07-19 2006-04-27 Новартис Аг Соли валсартана, фармацевтическая композиция на их основе и способ получения солей
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
BRPI0306907B8 (pt) * 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
RU2004137109A (ru) * 2002-05-17 2005-10-10 Новартис АГ (CH) Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда
AU2003276960A1 (en) * 2002-06-13 2003-12-31 Novartis Ag Calcium salts of indole derived statins
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
CA2519490A1 (en) * 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
AU2003223106A1 (en) * 2003-03-31 2004-10-25 Hetero Drugs Limited A novel amorphous form of valsartan
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
EA012392B1 (ru) * 2004-12-24 2009-10-30 Крка, Д.Д. Ново Место Твердая фармацевтическая композиция, содержащая валсартан
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
GB0503062D0 (en) * 2005-02-14 2005-03-23 Novartis Ag Combination of organic compounds
WO2007017897A2 (en) * 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
FR2886642B1 (fr) * 2005-06-06 2008-05-30 Sanofi Aventis Sa Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007071750A1 (en) * 2005-12-22 2007-06-28 Enantia, S.L. Intermediates and processes for the preparation of valsartan
EP2043607A2 (en) * 2006-06-23 2009-04-08 Usv Limited Process for the preparation of micronized valsartan
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
JP2010526126A (ja) * 2007-05-07 2010-07-29 シプラ・リミテッド バルサルタンの製造方法
DE602007000211D1 (de) * 2007-06-07 2008-12-11 Inke Sa Verfahren zur Gewinnung eines zur Gewinnung von Valsartan nützlichen Valsartan-Salzes
BRPI0817503B8 (pt) * 2007-10-05 2021-05-25 Sstarbio Pte Ltd derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
JP5653218B2 (ja) 2007-11-06 2015-01-14 ノバルティス アーゲー アンジオテンシン受容体アンタゴニスト／ブロッカーおよび中性エンドペプチダーゼ（ｎｅｐ）阻害剤の超構造に基づく二作用性医薬組成物
MX2010005198A (es) 2007-11-12 2010-05-20 Novartis Ag Composiciones liquidas que comprenden valsartan.
JP2013532707A (ja) 2010-08-03 2013-08-19 ノバルティス アーゲー 高結晶性バルサルタン
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
CA2824316C (en) * 2011-01-20 2020-07-07 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN105541741A (zh) * 2016-01-14 2016-05-04 青岛友诚高新技术有限公司 一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) * 2016-07-29 2016-12-21 陈欣怡 一种缬沙坦的新型固体形式
TWI648267B (zh) * 2016-09-02 2019-01-21 諾瑞特國際藥業股份有限公司 纈沙坦二鈉鹽新晶型
WO2018040065A1 (zh) * 2016-09-02 2018-03-08 诺瑞特国际药业股份有限公司 缬沙坦二钠盐的晶型
AU2017349757A1 (en) 2016-10-28 2019-05-30 Biocon Limited Amorphous trisodium sacubitril valsartan and process for its preparation
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
PL3658122T3 (pl) 2017-07-28 2021-10-18 Synthon B.V. Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
EP4037679A4 (en) * 2019-12-02 2023-11-08 Harman Finochem Limited PROCESS FOR PREPARING HIGHLY PURE VALSARTAN

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499017A (en) * 1983-06-06 1985-02-12 Pfizer Inc. Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
JPH05105698A (ja) * 1991-06-13 1993-04-27 Takeda Chem Ind Ltd ホスホン酸誘導体、その製造法および用途
WO1995024901A1 (en) 1994-03-17 1995-09-21 Ciba-Geigy Ag Treatment of diabetic nephropathy with valsartan
CA2214143A1 (en) 1995-04-07 1996-10-10 Marc De Gasparo Combination compositions containing benazepril or benazeprilat and valsartan
CA2232663C (en) * 1995-10-06 2008-04-08 Novartis Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
RU2275363C2 (ru) 2000-07-19 2006-04-27 Новартис Аг Соли валсартана, фармацевтическая композиция на их основе и способ получения солей

Also Published As

Publication number Publication date
CA2415962A1 (en) 2002-01-24
NO20030232L (no) 2003-01-17
US20070149587A1 (en) 2007-06-28
EP1313714B1 (en) 2008-08-27
AR069374A2 (es) 2010-01-20
US20080293791A1 (en) 2008-11-27
IL153882A0 (en) 2003-07-31
CA2415962C (en) 2010-07-06
CN1443176A (zh) 2003-09-17
US20030207930A1 (en) 2003-11-06
NO326504B1 (no) 2008-12-15
US9499499B2 (en) 2016-11-22
BR0112665A (pt) 2003-06-24
ECSP034436A (es) 2003-03-10
CZ303389B6 (cs) 2012-08-29
JP2004504307A (ja) 2004-02-12
US20140073677A1 (en) 2014-03-13
HK1055963A1 (en) 2004-01-30
DE60135560D1 (de) 2008-10-09
HUP0300731A2 (hu) 2003-09-29
CN100413852C (zh) 2008-08-27
SI1313714T1 (sl) 2009-02-28
IL153882A (en) 2009-09-01
CY1108559T1 (el) 2014-04-09
AU2001289672B2 (en) 2005-12-08
KR20030015888A (ko) 2003-02-25
WO2002006253A1 (en) 2002-01-24
MY152846A (en) 2014-11-28
ZA200300285B (en) 2004-03-25
PL360737A1 (en) 2004-09-20
PL205715B1 (pl) 2010-05-31
KR100529658B1 (ko) 2005-11-21
NZ523557A (en) 2004-12-24
AU8967201A (en) 2002-01-30
MY136446A (en) 2008-10-31
US20120329844A1 (en) 2012-12-27
PT1313714E (pt) 2008-11-03
US8278339B2 (en) 2012-10-02
DK1313714T3 (da) 2008-12-15
EP1313714A1 (en) 2003-05-28
SK552003A3 (en) 2003-07-01
CZ2003117A3 (cs) 2003-05-14
CN1680341A (zh) 2005-10-12
PE20020613A1 (es) 2002-08-07
JP4102664B2 (ja) 2008-06-18
MXPA03000525A (es) 2003-05-14
RU2275363C2 (ru) 2006-04-27
NO20030232D0 (no) 2003-01-17
ES2309090T3 (es) 2008-12-16
ATE406355T1 (de) 2008-09-15
AR032758A1 (es) 2003-11-26
CN1216873C (zh) 2005-08-31
HU229280B1 (en) 2013-10-28
HUP0300731A3 (en) 2006-05-29

Similar Documents

Publication Publication Date Title
SK287558B6 (sk) Soli valsartanu, ich použitie, spôsob ich výroby a farmaceutické prípravky obsahujúce tieto soli
JP5303370B2 (ja) バルサルタンの塩類
AU2001289672A1 (en) Valsartan salts
AU2009201898B2 (en) Valsartan salts
AU2007205815A1 (en) Salts of valsartan

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140717